GV20 oncotherapy Co., Ltd.

GV20 ONCOTHERAPY

GV20 Oncotherapy was started by an expert team trained at world-renowned universities. We are devoted to precision medicine development in cancer immuno-oncology. GV20 Oncotherapy has innovative antibody drug discovery and development platforms that integrate cancer genomics, immuno-oncology, and artificial intelligence. We are utilizing our technological advantages to search novel immunotherapy targets, screen fully human anti-tumor antibodies, and identify robust clinical biomarkers.

Technology platforms

Novel Immuno-Oncology Targets

Tumor-Specific Fully Human Antibodies

Robust Response Biomarkers

Atlas Genomics PlatformTumor profile,CRISPR screen &
antibody screen

Phial AI PlatformBig data & machine learning algorithms

company culture

Vision

Promote and realize precision medical services
Value

Looking for truth, embracing technological innovation, learning and progressing
Mission

Using functional genomics and bio-big data technology to advance cancer precision medicine innovation

investors

Linear Capital
IDG
WATSON

Vision

Value

Mission

Linear Capital

IDG

WATSON